Brain isoprenoids farnesyl pyrophosphate and geranylgeranyl pyrophosphate are increased in aged mice

Molecular Neurobiology

Volumn 46, Issue 1, 2012, Pages 179-185

  Hooff, Gero P ^a   Wood, W Gibson ^b   Kim, Ji Hyun ^c   Igbavboa, Urule ^b   Ong, Wei Yi ^c   Muller, Walter E ^a   Eckert, Gunter P ^a  

^a GOETHE UNIVERSITY   (Germany)

^b UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^c NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

Ageing; Alzheimer; Brain; Cholesterol; Isoprenoids; Mevalonate pathway

Indexed keywords

24 HYDROXYCHOLESTEROL; 25 HYDROXYCHOLESTEROL; 7 DEHYDROXYCHOLESTEROL; CHOLESTEROL; CHOLESTEROL DERIVATIVE; DESMOSTEROL; DOLICHOL; FARNESYL DIPHOSPHATE; GERANYLGERANYL PYROPHOSPHATE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; LANOSTEROL; LATHOSTEROL; MEVALONIC ACID; SQUALENE; SQUALENE SYNTHASE; UNCLASSIFIED DRUG;

AGE DISTRIBUTION; AGING; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BRAIN HOMOGENATE; BRAIN LEVEL; CONTROLLED STUDY; DEGENERATIVE DISEASE; FEMALE; GENE EXPRESSION; MOUSE; NONHUMAN; PROTEIN PRENYLATION;

EID: 84868111504     PISSN: 08937648     EISSN: 15591182     Source Type: Journal    
DOI: 10.1007/s12035-012-8285-6     Document Type: Article

References (44)

1. Reiss AB (2005) Cholesterol and apolipoprotein E in Alzheimer's disease. Am J Alzheimers Dis Other Demen 20(2):91-96 (Pubitemid 40547349)
2. Kovacs WJ, Faust PL, Keller GA, Krisans SK (2001) Purification of brain peroxisomes and localization of 3-hydroxy-3-methylglutaryl coenzyme A reductase. Eur J Biochem 268(18):4850-4859 (Pubitemid 32953800)
3. Brown MS, Goldstein JL (1980) Multivalent feedback regulation of HMG CoA reductase, a control mechanism coordinating isoprenoid synthesis and cell growth. J Lipid Res 21(5):505-517 (Pubitemid 11194847)
4. Wood WG, Eckert GP, Igbavboa U, Muller WE (2003) Amyloid beta-protein interactions with membranes and cholesterol: causes or casualties of Alzheimer's disease. Biochim Biophys Acta 1610 (2):281-290 (Pubitemid 36324471)
5. Wood WG, Igbabvoa U, Eckert GP, Muller WE (2007) Cholesterol-A Janus face molecule in the central nerous system. In: Lajtha A, Reith M (eds) Neural membranes and transport, vol XIV. Plenum Press, New York, p 513
6. Wood WG, Schroeder F, Avdulov NA, Chochina SV, Igbavboa U (1999) Recent advances in brain cholesterol dynamics: transport, domains, and Alzheimer's disease. Lipids 34(3):225-234 (Pubitemid 29169625)
7. Eckert GP, Wood WG, Muller WE (2001) Effects of aging and beta-amyloid on the properties of brain synaptic and mitochondrial membranes. J Neural Transm 108(8-9):1051-1064 (Pubitemid 32802102)
8. Eckert GP, Cairns NJ, Maras A, Gattaz WF, Muller WE (2000) Cholesterol modulates the membrane-disordering effects of betaamyloid peptides in the hippocampus: specific changes in Alzheimer's disease. Dement Geriatr Cogn Disord 11(4):181-186 (Pubitemid 30416021)
9. Eckert GP, Kirsch C, Muller WE (2003) Brain-membrane cholesterol in Alzheimer's disease. J Nutr Health Aging 7(1):18-23 (Pubitemid 36240747)
10. Ledesma MD, Martin MG, Dotti CG (2012) Lipid changes in the aged brain: effect on synaptic function and neuronal survival. Prog Lipid Res 51(1):23-35
11. Martin M, Dotti CG, Ledesma MD (2010) Brain cholesterol in normal and pathological aging. Biochim Biophys Acta 1801 (8):934-944
12. Wood WG, Igbavboa U, Eckert GP, Johnson-Anuna LN, Muller WE (2005) Is hypercholesterolemia a risk factor for Alzheimer's disease? Mol Neurobiol 31(1-3):185-192 (Pubitemid 41271202)
13. Eckert GP, Wood WG, Muller WE (2005) Statins: Drugs for Alzheimer's disease? J Neural Transm 112(8):1057-1071 (Pubitemid 40991521)
14. Wood WG, Schroeder F, Igbavboa U, Avdulov NA, Chochina SV (2002) Brain membrane cholesterol domains, aging and amyloid beta-peptides. Neurobiol Aging 23(5):685
15. Eckert GP, Wood WG, Muller WE (2010) Lipid Membranes and beta-amyloid: A harmful connection. Curr Protein Pept Sci 11 (5):319-325
16. Kirsch C, Eckert GP, Koudinov AR, Muller WE (2003) Brain cholesterol, statins and Alzheimer's Disease. Pharmacopsychiatry 36(Suppl 2):S113-S119 (Pubitemid 37346641)
17. Hooff GP, Wood WG, Muller WE, Eckert GP (2010) Isoprenoids, small GTPases and Alzheimer's disease. Biochim Biophys Acta 1801(8):896-905
18. Ong WY, Kim JH, He X, Chen P, Farooqui AA, Jenner AM (2010) Changes in brain cholesterol metabolome after excitotoxicity. Mol Neurobiol 41(2-3):299-313
19. Cole SL, Vassar R (2006) Isoprenoids and Alzheimer's disease: A complex relationship. Neurobiol Dis 22(2):209-222
20. McTaggart SJ (2006) Isoprenylated proteins. Cell Mol Life Sci 63 (3):255-267 (Pubitemid 43202309)
21. Edlund C, Soderberg M, Kristensson K (1994) Isoprenoids in aging and neurodegeneration. Neurochem Int 25(1):35-38 (Pubitemid 24229663)
22. Zhang Y, Appelkvist EL, Kristensson K, Dallner G (1996) The lipid compositions of different regions of rat brain during development and aging. Neurobiol Aging 17:869-875 (Pubitemid 27022740)
23. Igbavboa U, Avdulov NA, Schroeder F, Wood WG (1996) Increasing age alters transbilayer fluidity and cholesterol asymetry in synaptic plasma membrane of mice. J Neurochem 66(4):1717-1725 (Pubitemid 26090575)
24. Cutler RG, Kelly J, Storie K, Pedersen WA, Tammara A, Hatanpaa K, Troncoso JC, Mattson MP (2004) Involvement of oxidative stress-induced abnormalities in ceramide and cholesterol metabolism in brain aging and Alzheimer's disease. Proc Natl Acad Sci U S A 101(7):2070-2075 (Pubitemid 38229016)
25. Andersson M, Aberg F, Teclebrhan H, Edlund C, Appelkvist EL (1995) Age-dependent modifications in the metabolism of mevalonate pathway lipids in rat brain. Mech Ageing Dev 85 (1):1-14 (Pubitemid 26021798)
26. Soderberg M, Edlund C, Kristensson K, Dallner G (1990) Lipid compositions of different regions of the human brain during aging. J Neurochem 54(2):415-423
27. Eckert GP, Kirsch C, Muller WE (2001) Differential effects of lovastatin treatment on brain cholesterol levels in normal and apoE-deficient mice. Neuroreport 12(5):883-887 (Pubitemid 32281439)
28. Eckmann J, Eckert SH, Leuner K, Muller WE, Eckert GP (2012) Mitochondrial membranes in brain aging and neurodegeneration. Int J Biochem Cell Biol (in press)
29. Pallottini V, Marino M, Cavallini G, Bergamini E, Trentalance A (2003) Age-related changes of isoprenoid biosynthesis in rat liver and brain. Biogerontology 4(6):371-378 (Pubitemid 38088148)
30. Parentini I, Cavallini G, Donati A, Gori Z, Bergamini E (2005) Accumulation of dolichol in older tissues satisfies the proposed criteria to be qualified a biomarker of aging. J Gerontol A Biol Sci Med Sci 60(1):39-43 (Pubitemid 40321856)
31. Wood WG, Sun GY, Schroeder F (1989) Membrane properties of dolichol in different age groups of mice. Chem Phys Lipids 51(3-4):219-226 (Pubitemid 20011726)
32. Andersson M, Appelkvist EL, Kristensson K, Dallner G (1987) Age-dependent changes in the levels of dolichol and dolichyl phosphates in human brain. Acta Chem Scand B 41(2):144-146
33. Pullarkat RK, Reha H (1982) Accumulation of dolichols in brains of elderly. J Biol Chem 257(11):5991-5993 (Pubitemid 12029512)
34. Hooff GP, Volmer DA, Wood WG, Muller WE, Eckert GP (2008) Isoprenoid quantitation in human brain tissue: A validated HPLC-fluorescence detection method for endogenous farnesyl-(FPP) and geranylgeranylpyrophosphate (GGPP). Anal Bioanal Chem 392 (4):673-680
35. Eckert GP, Hooff GP, Strandjord DM, Igbavboa U, Volmer DA, Muller WE, Wood WG (2009) Regulation of the brain isoprenoids farnesyl-and geranylgeranylpyrophosphate is altered in male Alzheimer patients. Neurobiol Dis 35(2):251-257
36. Hooff GP, Patel N, Wood WG, Muller WE, Eckert GP, Volmer DA (2010) A rapid and sensitive assay for determining human brain levels of farnesyl-(FPP) and geranylgeranylpyrophosphate (GGPP) and transferase activities using UHPLC-MS/MS. Anal Bioanal Chem 398(4):1801-1808
37. Kim JH, Jittiwat J, Ong WY, Farooqui AA, Jenner AM (2010) Changes in cholesterol biosynthetic and transport pathways after excitotoxicity. J Neurochem 112(1):34-41
38. Folch J, Lees M, Sloane Stanley GH (1957) A simple method for the isolation and purification of total lipides from animal tissues. J Biol Chem 226(1):497-509
39. Crick DC, Waechter CJ, Andres DA (1994) Utilization of geranylgeraniol for protein isoprenylation in C6 glial cells. Biochem Biophys Res Commun 205(1):955-961 (Pubitemid 24381719)
40. Miquel K, Pradines A, Terce F, Selmi S, Favre G (1998) Competitive inhibition of choline phosphotransferase by geranylgeraniol and farnesol inhibits phosphatidylcholine synthesis and induces apoptosis in human lung adenocarcinoma A549 cells. J Biol Chem 273(40):26179-26186 (Pubitemid 28475855)
41. Zhou Y, Suram A, Venugopal C, Prakasam A, Lin S, Su Y, Li B, Paul SM, Sambamurti K (2008) Geranylgeranyl pyrophosphate stimulates gamma-secretase to increase the generation of Abeta and APP-CTFgamma. FASEB J 22(1):47-54
42. Murthy S, Tong H, Hohl RJ (2005) Regulation of fatty acid synthesis by farnesyl pyrophosphate. J Biol Chem 280 (51):41793-41804 (Pubitemid 43023147)
43. Kukar T, Murphy MP, Eriksen JL, Sagi SA, Weggen S, Smith TE, Ladd T, Khan MA, Kache R, Beard J, Dodson M, Merit S, Ozols VV, Anastasiadis PZ, Das P, Fauq A, Koo EH, Golde TE (2005) Diverse compounds mimic Alzheimer disease-causing mutations by augmenting Abeta42 production. Nat Med 11(5):545-550 (Pubitemid 40685978)
44. Hooff GP, Peters I, Wood WG, Muller WE, Eckert GP (2010) Modulation of cholesterol, farnesylpyrophosphate, and geranylgeranylpyrophosphate in neuroblastoma SH-SY5Y-APP695 cells: impact on amyloid beta-protein production. Mol Neurobiol 41(2-3):341-350